New Guideline Recommends CYP2C19 Genotyping Before Clopidogrel Therapy
Lydia Kariuki, Managing Editor at American Pharmacogenomics Association, posted on LinkedIn:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Jan 4, 2026, 17:02Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
-
Jan 4, 2026, 16:48Sleep Apnea: Full Breakdown from John Chuback
-
Jan 4, 2026, 16:36Edwin Ofori Atta on Permissive Hypertension For Ischemic Stroke
-
Jan 4, 2026, 16:27Nasrin Haghani on The Milli-Spinners: Breakthrough Technology Transforming Stroke Clot Removal
-
Jan 4, 2026, 16:10Godfrey Gandawa on Neuroplasticity in Stroke Rehabilitation
-
Jan 4, 2026, 14:53What Do Blood and Plasma Donors Think About Biobanking? A New Study Reveals Their Attitudes
-
Jan 4, 2026, 14:51First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
-
Jan 4, 2026, 14:51Shreya Agrawal: Top 5 Practical Hematology Lessons from 2025 – Mild Cytopenias are Rarely “Incidental” and More
-
Jan 4, 2026, 14:46We Analyzed Data From the Start of the COVID-19 Pandemic to 2024 – What Did We find?